KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $3.2 million.

  • Aquestive Therapeutics' Other Non-Current Assets fell 2437.35% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 2437.35%. This contributed to the annual value of $4.2 million for FY2024, which is 2234.28% down from last year.
  • Per Aquestive Therapeutics' latest filing, its Other Non-Current Assets stood at $3.2 million for Q3 2025, which was down 2437.35% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Other Non-Current Assets registered a high of $7.8 million during Q1 2021, and its lowest value of $3.2 million during Q3 2025.
  • For the 5-year period, Aquestive Therapeutics' Other Non-Current Assets averaged around $5.5 million, with its median value being $5.5 million (2023).
  • In the last 5 years, Aquestive Therapeutics' Other Non-Current Assets skyrocketed by 262048.61% in 2021 and then crashed by 2437.35% in 2025.
  • Aquestive Therapeutics' Other Non-Current Assets (Quarter) stood at $6.9 million in 2021, then fell by 6.55% to $6.5 million in 2022, then fell by 15.7% to $5.4 million in 2023, then fell by 22.34% to $4.2 million in 2024, then fell by 24.25% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $3.2 million for Q2 2025, and $4.2 million during Q1 2025.